MYD88 and colorectal cancer: Fusobacterium nucleatum has been detected in both colorectal cancer tissues and fecal samples, influencing treatment responses by targeting Toll-like receptor 4 (TLR4) and MyD88 immune pathways and specific microRNAs to activate autophagy, thus serving as a biomarker for colorectal cancer [22].